HOME >> MEDICINE >> NEWS
Novel drugs help solve Gleevec resistance

Bristol-Myers Squibb, which manufactures BMS-354825, paid for this study.

AMN107 is effective in patients with Gleevec-resistant ALL and CML

Francis Giles, M.D., professor of medicine in the Department of Leukemia, presented results of the second study, which found that the novel oral targeted therapy, AMN107, can produce responses not only in advanced and Gleevec-resistant CML patients, but also in patients with acute lymphocytic leukemia (ALL) associated with the "Philadelphia chromosome."

The AMN107 Phase I study has accrued 65 patients since opening in May 2004. Even though an optimal dose has yet to be established as no significant toxicities have yet been encountered, more than 50 percent of patients with Gleevec-resistant CML have responded, including cytogenetic and molecular responses in some patients so far, Giles says.

"While more study needs to be done to define a reasonable regimen for this drug, it has, so far, produced very important responses in patients who were desperately ill," he says. "Despite the response rate, we still have not seen any consistent severe side effects, so clearly AMN107 will have a different tolerability profile than Gleevec, a drug which is, in general, very well tolerated," he adds.

"Gleevec changed everything in CML. It has led to marked improvement in survival in all three phases of the disease, and it also has shown benefit in treating the 20 percent of ALL that shares the same genetic abnormality as CML, the Philadelphia chromosome," Giles says. "But a drug that can cope with resistance to Gleevec might do even better across the board, although it must be remembered that we are still learning how to optimally use Gleevec itself, a drug which we have only had available for a few years."

The clinical trial reported by Giles is unusual in that it allows for a rapid "intrapatient" dose escalation. Within the trial, patients are allowed to move to higher doses as they pr
'"/>

Contact: Nancy Jensen
nwjensen@mdanderson.org
713-794-1584
University of Texas M. D. Anderson Cancer Center
5-Dec-2004


Page: 1 2 3 4 5

Related medicine news :

1. Novel therapy tested in mice could chase away cat allergies
2. Novel antibiotic shows promise in shortening treatment duration of tuberculosis
3. Novel p53 gene-based therapy boosts immune system and reduces tumor size
4. Novel imaging technique shows abnormal brain anatomy in children with ADHD
5. Novel drug-antidote strategy provides greater control of drug action
6. Novel imaging technique shows lymph nodes, metastases in breast cancer without surgery
7. Novel delivery method for nutrients wins Kaye Innovation Award for Hebrew university students
8. Novel vitamin discovery offers clues for cancer chemotherapy and lipid disorders
9. Novel findings about neovessel formation
10. Novel MRI technique provides clear images of blood flow
11. Novelty-seeking teens may be more easily influenced by tobacco advertisements

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/19/2019)... ... July 19, 2019 , ... Juvly Aesthetics has announced ... its Director of Marketing and Sales. In his role, Okuley will be leading ... growth while furthering the company’s mission of empowering clients to look and feel ...
(Date:7/18/2019)... PLEASANTON, Calif. (PRWEB) , ... July 18, 2019 ... ... (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced ... a UroLift® Center of Excellence. The designation recognizes that Dr. Matsunaga has achieved ...
(Date:7/18/2019)... ... July 18, 2019 , ... We are ... 2019 Texas Monthly Super Doctor Rising Star ! Each year, Texas ... would trust for their own medical care. The Super Doctors research team then ...
(Date:7/17/2019)... PORTLAND, Ore. (PRWEB) , ... July 17, 2019 , ... ... way, at which damage to the teeth could occur, from the accident scene, to ... done before and created a paradigm shift for treatment. , They identified seven points, ...
(Date:7/17/2019)... ... July 17, 2019 , ... It took just several small incisions ... MD, to relieve pressure on the nerves under Amber Walck’s scalp, and suddenly her ... turned 30 last year, her debilitating headaches began without warning. About 39 million ...
Breaking Medicine News(10 mins):
(Date:7/17/2019)... WASHINGTON, Pa. (PRWEB) , ... July 17, 2019 ... ... new brand for its suite of CME subsidiaries: Global Learning Collaborative ... our CME enterprise, including growth in subsidiaries, scientific teams, leadership, and educational collaborations,” ...
(Date:7/17/2019)... (PRWEB) , ... July 17, 2019 , ... ... up with the MDA for their fourth annual national “Be Their Muscle” philanthropic ... to transform the lives of kids and adults with muscular dystrophy, ALS and ...
(Date:7/17/2019)... ... July 17, 2019 , ... Halcyon, one of the top ... processor of record. , As a result of the partnership, funeral home ... now also accept and process payments through it, securely and easily. , ...
Breaking Medicine Technology:
Cached News: